ClinicalTrials.gg
CompletedNCT03206229TPI-120Updated Jul 3, 2018

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

A Phase 1 interventional study of PEG-rhG-CSF and Neulasta (PEG-rhG-CSF) in Healthy Volunteers, sponsored by Adello Biologics, LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-03.

Sponsored by Adello Biologics, LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2017, 9 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).

All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.

Read the detailed description

The current study design was prepared to assess and compare the PK, PD, safety, tolerability of the Adello biosimilar candidate, TPI-120 and the US-licensed reference product, Neulasta® after administering a single subcutaneous 2 mg dose in healthy adult subjects in a crossover design. The primary PK parameters are AUC0-t, AUC0-inf, and Cmax, and the primary PD parameters are baseline-corrected AUEC0-t and Emax for ANC.

This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT).

All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Adello Biologics, LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to dosing), 19 - 55 years of age (inclusive), with (BMI) ≥ 19 and ≤ 30 kg/m2, and body weight not \< 50 kg or > 100 kg at the time of screening.
  2. Healthy as defined by:

    1. The absence of (in the opinion of the PI/designee) illness or surgery within 4 weeks prior to dosing.
    2. The absence of a clinically significant (in the opinion of the PI/designee) history of disease.
    3. WBC (white blood cell) > 4.0 x 109/L and \< 1.5 times the (ULN), (absolute neutrophil count) > 2.0 x 109/L and \< 1.5 times the upper limit of normal (ULN), count > 150 x 109/L, (aspartate aminotransferase) \< 2.5 time the upper limit of normal (ULN), ALT (alanine aminotransferase) \< 2.5 time the upper limit of normal (ULN), Serum \< 1.5 time the upper limit of normal (ULN) and Serum creatinine \< 1.5 time the upper limit of normal (ULN). [Refer to APPENDIX 1 for normal reference ranges]
    4. The absence of febrile (defined by a documented oral temperature of 101.5 °F or greater) or infectious illness within 1 week of first dosing.
    5. The absence of a clinically significant history of skin disorders, including psoriasis.
  3. Females of must be willing to use acceptable methods throughout the study, and for 30 days thereafter.
  4. Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be with amenorrhea for at least 1 year prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  5. Capable of consent.
  6. Male subjects willing to follow approved birth control method for the duration of the study, and for 30 days thereafter, such as (a double barrier method) vasectomy, condom with spermicide, condom with diaphragm or abstinence, subject should also not donate sperm during this time.

Exclusion criteria

Exclusion Criteria:

  1. Positive test for , , or .
  2. Illicit/illegal drug use as evidenced by a positive test for alcohol or drug screen at screening or check -in.
  3. Positive result for urine alcohol test at screening or check-in
  4. Tobacco use as evidenced by a positive cotinine result at screening or check-in.
  5. History of allergic reactions to pegfilgrastim, filgrastim, Escherichia coli (E. coli)-derived proteins, or other related drugs. History of allergic reactions or to acetate/acetic acid, polysorbate 20, or sorbitol.
  6. Hereditary fructose intolerance.
  7. Females with positive pregnancy tests at screening or check-in.
  8. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study or completing follow-up activities.
  9. or vital sign abnormalities at screening.
  10. History of significant alcohol abuse within one year prior to initial dosing or regular use of alcohol (more than 14 units of alcohol per week) within six months prior to initial dosing.
  11. History of drug abuse or use of illicit/illegal drugs within 1 year prior to initial dosing.
  12. No medications are permitted during the study. Exceptions are:

    1. Hormonal and Hormone Replacement Therapy (HRT),
    2. Thyroid replacement therapy i.e., liothyronine (T3) or levothyroxine (T4).
    3. Acetaminophen
  13. Donation of plasma within 7 days of dosing; blood donation or significant loss of blood within 30 days of dosing.
  14. Participation in a clinical trial involving the administration of an drug or marketed drug within 30 days prior to initial dosing (90 days for biologics) or concomitant participation in an investigational study involving no drug administration.
  15. Females who are breast-feeding or lactating.
  16. History of pulmonary infiltrate or pneumonia (radiologically confirmed) within 6 months prior to initial dosing.
  17. Any past exposure to recombinant human G-CSF products and/or a known history of prior treatment with blood-cell colony stimulating factors, interleukins or interferons.
  18. History of cancer
  19. Subjects who are on a special diet or who have self-reported a weight loss of more than 15 pounds within 1 month prior to initial dosing.
  20. Acute viral or bacterial infection within 1 month prior to initial dosing only if considered clinically significant in the opinion of the Principal Investigator/designee.
  21. History of any clinically significant disease or condition that, in the opinion of the Principal Investigator/designee, would render them unsuitable for inclusion in the study.
  22. Any vaccination (including influenza) within 90 days prior to initial dosing.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    TPI-120 (PEG-rhG-CSF)

    PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL

    Drug: PEG-rhG-CSF

  • Active comparator
    Neulasta (PEG-rhG-CSF)

    Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA

    Drug: Neulasta (PEG-rhG-CSF)

Interventions

  • PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule

    Also known as: PEGFILGRASTIM

  • PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule

    Also known as: PEGFILGRASTIM

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    To evaluate the pharmacokinetics

    Time frame: 56 days

  2. Area under the concentration-time curve from time zero to the time of the last non-zero concentration (AUC0-t)

    To evaluate the pharmacokinetics

    Time frame: 56 days

  3. Area under the concentration-time curve from time zero to infinity (extrapolated AUC0-inf)

    To evaluate the pharmacokinetics

    Time frame: 56 days

Secondary outcomes

  1. Safety Variable - Tolerability as measured by Injection Site reactions

    Tolerability as measured by Injection Site reactions

    Time frame: 1, 2, 4, and 24 hours postdose during each study period

  2. Safety Variable - Immunogenicity as measured by presence of Anti Drug Antibodies

    Immunogenicity as measured by presence of Anti Drug Antibodies

    Time frame: Day 1 of each study period & Day 22 of each study period

07

Study locations

1 site
  • WCCT Global Inc.
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Later on management will decide whether to share the data or not

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jun 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Jul 2, 2017
StartActual
Feb 13, 2017
Primary completionActual
Jun 2, 2017
CompletionActual
Jan 18, 2018
Last update
Jul 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03206229
Lead sponsor
Adello Biologics, LLC
Collaborators
inVentiv Health Clinical
Responsible party
Dr. Apinya Vutikullid (principal investigator, Adello Biologics, LLC) — Principal investigator
First posted
Jul 2, 2017
Start date
Feb 13, 2017
Primary completion
Jun 2, 2017
Completion
Jan 18, 2018
Last update
Jul 3, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegylated granulocyte colony-stimulating factor · Pegfilgrastim

Start the discussion